JAMA Psychiatry meta-analysis confirms deprexis efficacy
Amsterdam, Wednesday 22 February 2017 17.45 GMT
A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of deprexis for the treatment of depression. The software is one of GAIA’s developments. It has recently been licensed to Servier globally, except for the US and Japan. The meta-analysis was a truly global collaborative effort, as 26 researchers from the Netherlands, the US, UK, Australia, Germany, Switzerland, and Spain combined data from 13 randomized controlled trials with a total of 3876 study participants. Of the 13 trials, 5 had examined deprexis (38%), and 1199 of the participants came from deprexis studies (31%). There were no other interventions from Germany. The average effect size reported for deprexis studies was 0.53, compared to 0.28 for others.
